Mark Manfredi, Ikena Oncology president & CEO
November 29, 2022 11:04 AM ESTUpdated 04:56 PM
R&D

Ike­na On­col­o­gy drops an ear­ly-stage pro­gram as it looks to stretch its cash

Tyler Patchen

News Reporter

An­oth­er biotech is lin­ing up to cut a piece of its pipeline to ex­tend its cash­flow. The Boston-based, can­cer-cen­tered biotech Ike­na On­col­o­gy is look­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lex­i­con ends com­mer­cial work to fo­cus on R&D

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times